Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elelyso PK/PD/Safety in Pediatric Type 1 Gaucher Disease
NCT03021941Phase 4Withdrawn
- Sponsor
- Pfizer
- Start
- Jul 2019
- Primary completion
- Jun 2020
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of taliglucerase alfa in Type 1 Gaucher disease (GD1), sponsored by Pfizer. Planned start Jul 2019; status: withdrawn.
02
Drugs
taliglucerase alfa
03
Conditions
Type 1 Gaucher disease (GD1)
Beyond the preview
Go deeper on NCT03021941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021941.